Skip to main content
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
Corporate Vectors of Chronic Disease - Using Internal Industry Documents to Craft Counterstrategies.
Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk.
Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1.
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Implications of Race Adjustment in Lung-Function Equations.
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency.
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.